LadRx Corporation · OTC:LADX
LadRx — Investor Presentation (February 2024)
16 slides from LadRx's investor presentation, February 2024
Slide 1: Corporate Overview February 2024
OTCQB:LADX CORPORATE OVERVIEW February 2024 Non-Confidential
Slide 2: LadRx Corporation Safe Harbor Statement
LadRx Corporation Safe Harbor Statement THIS PRESENTATION CONTAINS FORWARD-LOOKING STATEMENTS THAT INVOLVE CERTAIN RISKS AND UNCERTAINTIES. SUCH STATEMENTS MAY BE PRECEDED BY THE WORDS “INTENDS,” “MAY,” “WILL,” “PLANS,” “EXPECTS,” “ANTICIPATES,” “PROJECTS,” “PREDICTS,” ESTIMATES,” “AIMS,” “BELIEVES,
Slide 3: Management and Board
Management and Board Board of Directors • Jennifer Simpson, PhD LadRx Chair of the Board. CEO of Panbela Therapeutics. Former CEO of Delcath, Oncology Stephen Snowdy, PhD Gilad Gordon, MD John Caloz Lead at Imclone, Product Director Oncology CEO R&D/Regulatory Consultant CFO Marketing at Ortho Biote
Slide 4: Despite Progress, Cancer is a Massive Burden Needing Solutions
Despite Progress, Cancer is a Massive Burden Needing Solutions In 2019, cancer claimed over 10 million lives worldwide1 Leading attributable causes (approx. half of cancers are attributable) are smoking, alcohol use, and high BMI 1 Cancer is the second leading cause of death in the US, behind heart
Slide 5: Investment Highlights
Investment Highlights LadRx has developed elegant tumor targeting and release molecules called LADR that are based on small molecular entities (no complex antibodies or nanoparticles) allowing for higher dosing, lower off-target toxicity, and no need for screening patients for presence of antibody t
Slide 6: LADR=Linker-Activated Drug Release
LADR=Linker-Activated Drug Release LADR-based drugs take advantage of circulating albumin as trojan horse: ➢ Major source of amino acids for tumors* ➢ Tumors use as carrier for metabolites, hormones, nutrients* ➢ Undergoes macropinocytosis* ➢ Accumulates in tumors due to EPR* ➢ Long half life* LADR:
Slide 7: Aldoxorubicin: 1st Gen LADR-Based Drug Has Proven Higher Dosing with Improved Safety
Aldoxorubicin: 1st Gen LADR-Based Drug Has Proven Higher Dosing with Improved Safety in Human Trials Compared to Native Doxorubicin ➢ LADR allows for 3X higher dosing or more of doxorubicin When attached to LADR backbone, ➢ Aldoxorubicin crosses the Blood-Brain doxorubicin has Barrier been dosed in
Slide 8: Next-Gen LADRs: LADR 7, 8, 9, 10
Next-Gen LADRs : LADR 7, 8, 9, 10 • High-throughput screening yielded four compounds selected for evaluation: • LADR 7: Auristatin-E with Ketone Linker • LADR 8: Auristatin-E with Ester Linker • LADR 9: Maytansine with Ketone Linker • LADR 10: Maytansine with Ester Linker • Auristatins and Maytansin
Slide 9: LADRs 7 and 8 anti-cancer drugs in PDX/CDX models: Melanoma
LADRs 7 and 8 are powerful anti-cancer drugs in multiple PDX/CDX cancer models: Melanoma
Slide 10: LADRs 7 and 8 anti-cancer drugs in PDX/CDX models: Ovarian
LADRs 7 and 8 are powerful anti-cancer drugs in multiple PDX/CDX cancer models: Ovarian
Slide 11: LADRs 7 and 8 anti-cancer drugs in PDX/CDX models: Non-Small Cell Lung Cancer
LADRs 7 and 8 are powerful anti-cancer drugs in multiple PDX/CDX cancer models: Non-Small Cell Lung Cancer
Slide 12: As Are LADRs 9 and 10
.As are LADRs 9 and 10 w of the antitumor activity of maytansine and bumin-binding drugs in various human PDX and nograft tumor me glee rel els e. IEA bos 4 ABB 1 of b ils Flee z 3k & glelle/s lode ge glg/22 be eee 8 tle] eg mad a vPP EEE oem ARIE 25 & sls|s.3 cae [Ts 3 ame |e ora [ans | , ene ee oy
Slide 13: All Four LADR Candidates Meet Initial Development Criteria
All Four LADR Candidates Meet Initial Development Criteria Maytansinoid LADR s (LADR- Auristatin LADR s 9 and (LADR-7 and LADR-8) LADR-10) Selective Binding to Albumin and Stable in Plasma Payload Releases at pH 4 Robust Anti-Tumor Activity in Multiple Tumor Types Durable Responses Averaged 60‒90 Da
Slide 14: Next-gen LADR Nearing IND
Next-gen LADR Nearing IND ✓ Stability in plasma (mouse, rat, dog, monkey, human) ✓ pH-dependent release ✓ Rat and mouse MTD ✓ In-vitro efficacy ✓ In-vivo efficacy (small and large tumor PDX and CDX) ✓ Non-GLP rodent tox ✓ CMC ✓ Manufacturing of clinical batch under Good Manufacturing Practices (GMP)
Slide 15: Status of Arimoclomol and Aldoxorubicin
Status of Arimoclomol and Aldoxorubicin In June 2023, LadRx entered an agreement with Xoma, Inc. in which economic rights to arimoclomol and aldoxorubicin were transferred to Xoma, Inc. In exchange for the economic rights to arimoclomol and aldoxorubicin, LadRx received () or will receive: ✓ $5M gr
Slide 16: Summary
Summary LadRx has developed a targeted delivery platform for chemotherapeutic agents that takes advantage of the concentration of albumin in solid tumors. Being small molecules, the agents are easier/cheaper to manufacture than macromolecules, confer solubility, cross the blood-brain barrier, and ar